Work

A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps4604

Authors: David F. McDermott, Jeffrey R. Infante, Martin Henner Voss, Robert J. Motzer, John B. A. G. Haanen, Simon Chowdhury, Rodolfo F. Perini, Robert Iannone, Rachel Hodge, David Figueroa, Benjamin B. Suttle, Alicia Allred, Stephen D. Rubin, Brian I. Rini

Institutions: Beth Israel Deaconess Medical Center, Sarah Cannon, Tennessee Oncology, Memorial Sloan Kettering Cancer Center, The Netherlands Cancer Institute, Sarah Cannon Research Institute, Hospital of the University of Pennsylvania, Merck & Co., Inc., Rahway, NJ, USA (United States), GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States), Cleveland Clinic

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2593884778

Cites:

Cited by: 6

Related to: 10